CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

BACMUNE (MV130)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D007239 Infection NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial on the Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to SARS-CoV-2 Infection in Healthcare Personnel

The purpose of this trial is to assess the effect of immunotherapy with the bacterial preparation MV130 on the spread and course of SARS-CoV-2 infection in highly exposed subjets, as is the case with healthcare personnel.

NCT04452643 Covid19 Biological: BACMUNE (MV130) Other: Placebo
MeSH:Infection

Primary Outcomes

Description: Incidence of subjects with COVID-19, defined by the presence of: Fever Any of the respiratory signs and/or symptoms: cough, dyspnea, respiratory failure, runny nose/nasal obstruction. Positive test for SARS-COV-2 (PCR o serology)

Measure: Incidence of subjects with COVID-19

Time: 60 days

Description: Incidence of severe COVID-19, defined by CURB > 2 and/or death

Measure: Severity of COVID-19

Time: 60 days

Secondary Outcomes

Description: Rate of subjects with seroconversion to SARS-CoV-2 (negative serology at the beginning of the study and positive at the end of the study

Measure: Seroconversion to SARS-CoV-2

Time: 60 days

Description: Rate of subjects with any symptoms, whether confirmed, probable or suspected, according to the WHO definition

Measure: Subjects with symptoms

Time: 60 days

Description: The effect of the treatment on the severity of the disease will be measured based on the rate of subjects requiring hospital admission for COVID-19

Measure: Hospital admission due to COVID-19

Time: 60 days

Description: The effect of the treatment on the severity of the disease will be measured based on the rate of subjects who require admission to an intensive care unit for COVID-19 • Time from confirmation of SARS-CoV-2 infection to the appearance of symptoms.

Measure: Admission to an intensive care unit due to COVID-19

Time: 60 days

Description: Elapsed time until the first symptoms of COVID-19 appears to hospitalization due to COVID-19.

Measure: Elapsed time until hospitalization

Time: 60 days

Description: Elapsed time until the first symptoms of COVID-19 appears to admission into an intensive care unit pro COVID-19.

Measure: Elapsed time until admission into an care unit for COVID-19

Time: 60 days

Description: Elapsed time until the first symptoms of COVID-19 appears to death from any cause not related to COVID-19.

Measure: Elapsed time until death not related to COVID-19

Time: 60 days

No related HPO nodes (Using clinical trials)